STAT+: Next-gen Duchenne drug from Entrada disappoints

Entrada Therapeutics' next-generation drug for Duchenne muscular dystrophy disappointed in an early trial, raising questions about the company's competitiveness. The drug is designed to help patients produce shortened but still functional forms of dystrophin. Scientists have devised ways to redesign these molecules for better results.